Latest news
Centanafadine in ADHD: Clinical Significance of the First Triple Reuptake Inhibitor for ADHD - Psychiatric TimesPsychiatric Times · Mon, 03 Aug 2026 18:23:02 GMTADHD: FDA Approves New CNS Drug Simtriyo for Adults and Children - HealthlineHealthline · Wed, 29 Jul 2026 07:00:00 GMTFDA Approves ‘First-in-Class’ NDSRI for ADHD in Adults and Children - AOL.comAOL.com · Wed, 29 Jul 2026 07:00:00 GMTCentanafadine Receives FDA Approval for the Treatment of ADHD - ADDitudeADDitude · Wed, 29 Jul 2026 07:00:00 GMTFDA Approves Simtriyo | PharmExec - Pharmaceutical ExecutivePharmaceutical Executive · Mon, 27 Jul 2026 19:22:31 GMTFDA Approves First-in-Class Centanafadine for Treatment of ADHD - Drug TopicsDrug Topics · Mon, 27 Jul 2026 13:12:28 GMTFDA Approves First NDSRI for ADHD in Adults and Children - MedscapeMedscape · Mon, 27 Jul 2026 07:00:00 GMTFDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’ - Fierce PharmaFierce Pharma · Mon, 27 Jul 2026 07:00:00 GMT